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S U M M A R Y
Objectives: The aim of this study was to delineate the association between high macrophage migration
inhibitory factor (MIF) and interleukin 10 (IL-10) levels in the early phase of sepsis and rapidly fatal outcome.
Methods: One hundred and ﬁfty-three adult subjects with the main diagnosis of severe sepsis (including
septic shock) admitted directly from the emergency department of two tertiary medical centers and one
regional teaching hospital between January 2009 and December 2011, were included prospectively. MIF
and IL-10 levels were measured and outcomes were analyzed by Cox regression analysis according to the
following outcomes: rapidly fatal outcome (RFO, death within 48 h), late fatal outcome (LFO, death
between 48 h and 28 days), and survival at 28 days.
Results: Among the three outcome groups, IL-10 levels were signiﬁcantly higher in the RFO group (p <
0.001) and no signiﬁcant differences were seen between the LFO and survivor groups. After Cox
regression analysis, each incremental elevation of 1000 pg/ml in both IL-10 and MIF was independently
associated with RFO in patients with severe sepsis. Each incremental elevation of 1000 pg/ml in IL-10
increased the RFO risk by a factor of 1.312 (95% conﬁdence interval 1.094–1.575; p = 0.003); this was the
most signiﬁcant factor leading to RFO in patients with severe sepsis.
Conclusions: Patients with RFO exhibited simultaneously high MIF and IL-10 levels in the early phase of
severe sepsis. Incremental increases in both IL-10 and MIF levels were associated with RFO in this patient
group, and of the two, IL-10 was the most signiﬁcant factor linked to RFO.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Sepsis is one of the main causes of death among hospitalized
patients, and current evidence suggests that sepsis care bundles* Corresponding author. Tel.: +886 2 23123456x65355; fax: +886 2 23955072.
E-mail address: hsporen@ntu.edu.tw (P.-R. Hsueh).
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http://dx.doi.org/10.1016/j.ijid.2013.12.006can reduce mortality rates in septic patients.1 However, identifying
the risk factors for rapidly fatal outcome (RFO) in septic patients
remains a great challenge. It has been suggested that during sepsis
the immune response reﬂects an interaction between pro-
inﬂammatory and anti-inﬂammatory mediators.2 The early-phase
systemic inﬂammatory response syndrome (SIRS) is characterized
by the expression of pro-inﬂammatory mediators and is followed
by the development of a compensatory anti-inﬂammatory
response syndrome (CARS).
An exaggerated early-phase response, which occurs by the
expression of pro-inﬂammatory mediators, can lead to earlyociety for Infectious Diseases. Open access under CC BY-NC-ND license.
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levels of macrophage migration inhibitory factor (MIF), a key
mediator of the systemic inﬂammatory response, which predicts
early death from severe sepsis.4,5 In a previous study, we found
that positive sputum Klebsiella pneumoniae cultures were able to
predict RFO in septic patients from the medical intensive care unit
(ICU).6 Signiﬁcantly elevated levels of interleukin 10 (IL-10), a
potent anti-inﬂammatory mediator, were found in patients with
bronchoalveolar lavage cultures positive for K. pneumoniae as
compared to other pathogens.7 In a mouse model of systemic K.
pneumoniae infection, an elevation in IL-10 was observed within
24 h and peaked within 12 h after infection. Rukavina et al.
speculated that in infected animals, the dynamics of the increased
IL-10 production during the early phase was responsible for the
inadequate inﬂammatory reaction and control of the infection.8 All
these ﬁndings suggest that the simultaneous appearance of high
MIF (a pro-inﬂammatory mediator) and IL-10 (an anti-inﬂamma-
tory mediator) levels in the early phase of sepsis could explain, in
patients with severe sepsis, the association with RFO.
In the present study we investigated MIF and IL-10 concentra-
tions in patients with severe sepsis to examine their association
with RFO.
2. Materials and methods
2.1. Study population
Adult patients (>18 years of age) with the main diagnosis of
severe sepsis (including septic shock) and admitted directly from
the emergency department (ED) were recruited in this prospective
observational study at the medical ICU of Taoyuan General
Hospital (TYGH; a 20-bed unit in a 600-bed regional teaching
hospital) between January 2009 and June 2010, at the National
Taiwan University Hospital (NTUH; a 44-bed unit in a 1200-bed
tertiary medical center), and at the Far-Eastern Memorial Hospital
(FEMH; a 20-bed unit in a 1000-bed tertiary medical center) during
the period October 2010 to December 2011. Patients transferred
from other ICU units or from a general ward were excluded.
Patients were enrolled in the study only after their legal
representatives had signed informed consent forms and blood
samples had been collected in the morning between 6 a.m. to 8
a.m. within 24 h of admission to the medical ICU. The study
protocol complied with the Declaration of Helsinki and was
approved by the ethics committees of TYGH (TYGH99024), NTUH
(201104074RC), and FEMH (100043-E).
2.2. Clinical information
Gender, age, and underlying diseases of the patients were
recorded. Clinical variables that were recorded during the ﬁrst 24 h
in the medical ICU included the presence of an infection focus such
as pneumonia, urinary tract infection (UTI), or intra-abdominal
infection (IAI), organ dysfunction, coagulation proﬁle, the Acute
Physiology and Chronic Health Evaluation (APACHE) II score, and
the results of various cultures.
2.3. Deﬁnitions
The rapidly fatal outcome (RFO) group was deﬁned as patients
who died within the ﬁrst 48 h after medical ICU admission. The late
fatal outcome (LFO) group was deﬁned as patients who died more
than 48 h after medical ICU admission. The survivor group was
deﬁned as patients who lived more than 28 days after medical ICU
admission. A clinical diagnosis of pneumonia, UTI, or IAI was made
at the time of medical ICU admission if the patient presented with
associated symptoms, laboratory data, or radiographic evidence.9Specimens for microbiological studies, including sputum, urine,
body ﬂuid, and at least two sets of blood cultures, were obtained
according to clinician judgment before the administration of
antibiotics in the ED or medical ICU. Blood culture specimens were
inoculated into BACTEC culture bottles using the BACTEC 9240
system (Becton Dickinson, Cockeysville, MD, USA). The adequacy of
empirical antibiotics was determined in patients with microbio-
logical diagnoses according to the in vitro sensitivities of
microorganisms. Severe sepsis was deﬁned as sepsis associated
with acute organ dysfunction, including the following: cardiovas-
cular dysfunction (systolic blood pressure <90 mmHg, mean
arterial pressure <65 mmHg, or a reduction in systolic blood
pressure >40 mmHg), respiratory dysfunction (bilateral pulmo-
nary inﬁltrates with a ratio of partial pressure of arterial oxygen to
fraction of inspired oxygen <300 mmHg), renal dysfunction
(serum creatinine levels >2 mg/dl or urine output <0.5 ml/kg/h
for 2 h), hepatic dysfunction (total serum bilirubin levels >2 mg/
dl), hematologic dysfunction (platelet counts <100  109/l), and
metabolic dysfunction (serum lactate levels >2 mmol/l).10,11
2.4. Data collection
Blood was collected in sterile test tubes containing heparin and
centrifuged at 1000  g for 10 min. Plasma was aliquoted into
Eppendorf tubes and stored at 70 8C until analysis. Plasma MIF
and IL-10 concentrations were measured using sandwich enzyme-
linked immunosorbent assays (ELISA) in accordance with the
manufacturers’ instructions (RayBiotech, Norcross, GA, USA for
MIF; Biolegend, San Diego, CA, USA for IL-10). The minimum
detectable concentration was <6 pg/ml for MIF and 2 pg/ml for IL-
10. The intra-assay variation was less than 10% for MIF and
between 5.2% and 6.1% for IL-10. The inter-assay variation was
<12% for MIF and between 6.7% and 7.8% for IL-10. These data were
provided by the manufacturers.
2.5. Statistical analysis
The data were compiled and analyzed with SPSS 15.0 (SPSS Inc.,
Chicago, IL, USA). Comparisons among the three outcome groups
were assessed using the Kruskal–Wallis test for continuous
variables and the Chi-square or Fisher’s exact test for categorical
variables when appropriate. Multivariate Cox regression analysis,
after adjustment for age and gender, was used to identify the
signiﬁcant independent factors predicting RFO. Odds ratios and the
corresponding 95% conﬁdence intervals (95% CI) were calculated. A
p-value of <0.05 was considered statistically signiﬁcant.
3. Results
A total of 153 patients with the main diagnosis of severe sepsis
were enrolled in the medical ICU during the study period. Ninety-
ﬁve of these patients were male, and the mean age of all patients
was 71 years (range 29–95 years). Forty-four patients (28.7%) died
within 28 days and 12 patients (27.3%) had RFO. No signiﬁcant
differences existed among the three outcome groups for age,
gender, or Charlson co-morbidity index. There were signiﬁcant
differences among the three groups with regard to organ
dysfunction, including cardiovascular, metabolic, and hematologic
dysfunction, APACHE II scores, and Glasgow coma scale scores
(Table 1). In the post-hoc analysis, the RFO group had a
signiﬁcantly higher incidence of cardiovascular, metabolic, and
hematologic dysfunction as compared to the survivor group.
However, no differences were seen between the RFO and LFO
groups in organ dysfunction of the above-mentioned organs.
Severe sepsis was caused by Gram-negative bacteria in 79
patients (51.6%), Gram-positive bacteria in 26 patients (16.9%), and
Table 1
Patient characteristics on the day of ICU admissiona
Characteristics RFO group
(n = 12)
LFO group
(n = 32)
Survivor group
(n = 109)
p-Value
Age, years 67.5  17.8 73.8  11.8 71.4  14.7 0.599
Gender, male/female 6/6 21/11 68/41 0.598
Charlson co-morbidity index 1.8  1.0 2.2  2.0 2.5  2.3 0.781
Underlying medical conditions
Alcohol intake 2 (16.7%) 3 (9.4%) 14 (12.8%) 0.708
Diabetes mellitus 6 (50.0%) 13 (40.6%) 38 (34.9%) 0.525
Liver cirrhosis 2 (16.7%) 5 (15.6%) 6 (5.5%) 0.074
Uremia 1 (8.3%) 2 (6.2%) 8 (7.3%) 0.999
Malignancy 1 (8.3%) 5 (15.6%) 14 (12.8) 0.921
Acute organ dysfunction
APACHE II score 26.8  6.7 25.1  7.6 22.0  7.5 0.046
Glasgow coma scale score 5.7  3.4 7.8  3.7 8.6  3.7 0.033
Cardiovascular dysfunction 10 (83.3%)b 26 (81.2%) 66 (60.6%) 0.042
Respiratory dysfunction 6 (50.0%) 12 (37.5%) 44 (40.4%) 0.762
Renal dysfunction 7 (63.6%) 16 (51.6%) 55 (52.9%) 0.789
Hepatic dysfunction 2 (16.7%) 5 (15.6%) 12 (11.0%) 0.645
Metabolic dysfunction 11 (91.7%)b 25 (80.6%) 61 (58.1%) 0.008
Hematologic dysfunction 7 (58.3%)b 11 (34.4%) 20 (18.3%) 0.004
ICU, intensive care unit; RFO, rapidly fatal outcome; LFO, late fatal outcome; APACHE, Acute Physiology and Chronic Health Evaluation.
a All data are presented as the mean  standard deviation, or number (%).
b Comparison between the RFO and survival groups with p < 0.05.
Pathog
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23 patients (15.0%); one of them had two different Gram-positive
bacteria, 11 had at least two different Gram-negative bacteria, and
11 had both Gram-positive and Gram-negative bacteria. The
remaining 51 patients had negative culture results. A total of 129
pathogens were isolated from 102 patients in this study. Blood
cultures were positive in 44 patients (28.7%). K. pneumoniae was the
most common pathogen in all positive cultures (23.2%, 30/129) and
in positive blood cultures (25.0%, 11/44). A total of 12 pathogens
with antimicrobial resistance were isolated from 11 patients: eight
were methicillin-resistant Staphylococcus aureus, two were extend-
ed-spectrumb-lactamase (ESBL)-producing Escherichia coli, and two
were ESBL-producing K. pneumoniae. There were no signiﬁcant
differences in infection foci, pathogens, bacteremia, resistant
pathogens, and antibiotic adequacy among the three groups.
The MIF levels were highest in the RFO group and lowest in the
survivor group; however, no signiﬁcant differences were found
among the three groups (median 5616.4 pg/ml, interquartile rangeTable 2
Infection foci and microbiological data obtained during admission to the ICUa
RFO group
(n = 12)
Infection focus
Pneumonia 7 (58.3%) 
Urinary tract infection 4 (33.3%) 
Intra-abdominal infection 2 (16.7%) 
Other 2 (16.7%) 
en
Gram-positive bacteria 3 (25.0%) 
Gram-negative bacteria 6 (50.0%) 
Fungi 0 (0.0%) 
Bacteremia
Gram-positive bacteremia 1 (8.3%) 
Gram-negative bacteremia 3 (25.0%) 
Fungemia 0 (0.0%) 
Resistant pathogen
Gram-positive resistant strain 2 (16.7%) 
Gram-negative resistant strain 0 (0.0%) 
Microbiological diagnosis and antibiotic adequacy
With microbiological diagnosis 
Adequate antibiotics 4 (50.0%) 
Inadequate antibiotics 4 (50.0%) 
Without microbiological diagnosis 4 (33.3%) 
ICU, intensive care unit; RFO, rapidly fatal outcome; LFO late fatal outcome.
a All data are presented as numbers (%).(IQR) 1547.9–10275.4 pg/ml in the RFO group; median 1688.6 pg/
ml, IQR 1030.5–13161.0 pg/ml in the LFO group; median 1439.6
pg/ml, IQR 726.3–6619.6 pg/ml in the survivor group) (Figure 1, p =
0.081). The IL-10 levels differed signiﬁcantly among the three
outcome groups (Figure 2, p < 0.001). The post-hoc analysis also
showed signiﬁcant differences in the IL-10 levels between the RFO
(median 1926.6 pg/ml, IQR 166.5–3120.2 pg/ml) and LFO (median
71.7 pg/ml, IQR 28.8–371.0 pg/ml; p = 0.031) groups and between
the RFO and survivor (median 35.4 pg/ml, IQR 10.8–136.4 pg/ml; p
< 0.001) groups, but no differences in the IL-10 levels existed
between the LFO and the survivor groups.
The results of the Cox regression analysis for factors associated
with RFO are summarized in Table 3. Univariate analysis revealed
several factors that were associated with RFO, and these included
APACHE II score, Glasgow coma scale score, cardiovascular,
metabolic, and hematologic dysfunction, and each 1000 pg/ml
incremental elevation in IL-10 levels. Multivariate analysis, after
adjustment for age and gender, revealed that cardiovascular,LFO group
(n = 32)
Survivor group
(n = 109)
p-Value
15 (46.9%) 61 (56.0%) 0.663
5 (15.6%) 28 (25.7%) 0.396
6 (18.8%) 13 (11.9%) 0.567
7 (21.9%) 9 (8.3%) 0.079
4 (12.5%) 19 (17.4%) 0.510
20 (62.5%) 53 (48.6%) 0.375
4 (12.5%) 4 (3.7%) 0.139
2 (6.3%) 6 (5.5%) 0.730
9 (28.1%) 19 (17.4%) 0.322
3 (9.4%) 1 (0.9%) 0.060
2 (6.3%) 4 (3.7%) 0.255
1 (3.1%) 3 (2.8%) 0.706
0.315
20 (76.9%) 45 (66.2%)
6 (23.1%) 23 (33.8%)
6 (18.8%) 41 (37.6%)
Figure 2. Box plots of interleukin 10 (IL-10) levels among patients. Box plots show
the median (center line), the interquartile range (the 25th to the 75th percentile;
box), and the 5th and 95th percentiles (whiskers). p-Values determined by the
Kruskal–Wallis test for comparisons among groups were less than 0.001. For
participants who had a rapidly fatal outcome vs. survivors, the p-value was less than
0.001. For those who had a rapidly fatal outcome vs. late fatal outcome, the p-value
was 0.031.
Figure 1. Box plots of macrophage migration inhibitory factor (MIF) levels among
patients. Box plots show the median (center line), interquartile range (the 25th to
the 75th percentile; box), and the 5th and 95th percentiles (whiskers). p-Values
determined by the Kruskal–Wallis test for comparisons among groups were 0.081.
Table 3
Multivariate Cox proportion hazard model of prognostic factors associated with rapidl
Factor Univariate analysis 
HR 95% CI 
Age (years) 1.002 0.981–1.023 
Gender (male) 0.921 0.502–1.690 
Cardiovascular dysfunction 2.541 1.181–5.468 
Metabolic dysfunction 3.152 1.402–7.087 
Hematologic dysfunction 2.729 1.494–4.988 
MIF (each increment of 1000 pg/ml) 1.009 1.000–1.019 
IL-10 (each increment of 1000 pg/ml) 1.407 1.217–1.626 
HR, hazard ratio; CI, conﬁdence interval; MIF, macrophage migration inhibitory factor;
a Signiﬁcant; p < 0.05.
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elevation of 1000 pg/ml in IL-10 and MIF levels were indepen-
dently associated with RFO in patients with severe sepsis. Each
incremental elevation of 1000 pg/ml in IL-10 increased the risk of
RFO by a factor of 1.312 (95% CI 1.094–1.575; p = 0.003) and this
was the most signiﬁcant factor leading to RFO in patients with
severe sepsis.
4. Discussion
Analysis of the clinical data and MIF and IL-10 levels in 153
patients with severe sepsis revealed that the secretion of pro-
inﬂammatory mediators such as MIF and anti-inﬂammatory
mediators such as IL-10 occurred spontaneously in the early
phase of severe sepsis. We also found that each incremental
elevation of 1000 pg/ml in IL-10 and MIF levels was independently
associated with RFO in patients with severe sepsis. These ﬁndings
are consistent with our theory that a simultaneous increase in MIF
and IL-10 levels in patients with severe sepsis could be associated
with RFO.
Classically the two-phase model of sepsis consists of an initial
pro-inﬂammatory phase followed by an anti-inﬂammatory
phase. Our study clearly demonstrated that both pro- and anti-
inﬂammatory cytokines such as MIF and IL-10 occurred
simultaneously in patients with severe sepsis. Tamayo et al.
reported similar results, with both pro- and anti-inﬂammatory
responses being simultaneously regulated in the early phase of
severe sepsis.12 IL-10 has been found to be a powerful predictor of
28-day and hospital mortality in patients with severe sepsis at
admission, 48 h,13 72 h,14 and even up to 15 days.15 In three
recent studies using multiplex analysis of cytokines, IL-10 was
not a signiﬁcant predictor of early (<48 h) mortality16 or even
mortality at 28 days16,17 in two of the studies, but in the other it
emerged as a signiﬁcant predictor of early mortality (<72 h) and
mortality at 28 days.18 Our ﬁndings also demonstrated that an
incremental elevation in IL-10 levels was the most powerful
predictor of RFO in patients with severe sepsis. There are several
possible reasons to explain these discrepant ﬁndings. First, the
sources of patients were different. None of the three studies
mentioned the source of the patients.16–18 Our study clearly
stated that the patients had been transferred from the ED to the
medical ICU, thus ensuring uniﬁed clinical characteristics of the
participants. Second, the timing of blood sample collections was
different. One study mentioned that blood samples were
collected between 10:00 and 12:00 a.m.,16 while another study
mentioned that they were collected at the time of admission.17
Both our study and that of Andaluz-Ojeda et al. collected blood
samples within the ﬁrst 24 h following ICU admission.18 Third,
these studies used different assays to measure cytokine levels.
Three studies used multiplex cytokine assays, while our studyy fatal outcome in patients with severe sepsis
Multivariate analysis
p-Value HR 95% CI p-Value
0.853 1.019 0.991–1.047 0.180
0.791 0.844 0.418–1.704 0.637
0.017a 2.497 1.104–5.646 0.028a
0.005a 2.827 1.119–7.142 0.028a
0.001a 2.849 1.343–6.047 0.006a
0.053 1.013 1.003–1.023 0.012a
<0.001a 1.312 1.094–1.575 0.003a
 IL-10, interleukin 10.
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kines.16–18 While cytokine detection by Luminex xMAP technol-
ogy is comparable to ELISA measurements, inter-institutional
variations could still exist.
Previous studies suggested that high MIF levels and an
inappropriate adrenal response were associated with early death
in patients with severe sepsis.4,5 Our results also demonstrated
incremental elevations in MIF levels to be one of the independent
predictors of RFO in patients with severe sepsis. These ﬁndings
support the initial pro-inﬂammatory phase that classically occurs in
the two-phase model of sepsis. The intraperitoneal injection of
recombinant MIF in a rat model of sepsis induced disseminated
intravascular coagulation (DIC).19 Continuously high levels of
MIF, soluble ﬁbrin, and low protein C activity were also found in
septic patients with DIC.20 There was a weak but signiﬁcant
correlation between both peak MIF/peak protein C (r = 0.302,
y = 0.74x + 45.8; p < 0.0001) and total MIF/total protein C
(r = 0.278, y = 0.218x + 70.0; p < 0.0001) in a study conducted by
Gando et al. (personal communication). We postulated a signiﬁ-
cantly negative correlation between MIF and protein C activity levels
that induced DIC in patients with RFO, but this needs to be further
explored in our future work.
IL-10 is a potent endogenous immunosuppressant cytokine that
is secreted by a variety of cell types, including T helper (Th) 2 cells,
monocytes/macrophages, dendritic cells, and epithelial cells. It
inhibits Th1 pro-inﬂammatory cytokines, including interferon
gamma (IFN-g), tumor necrosis factor alpha (TNF-a), IL-1b, IL-8,
and IL-12.21 MIF is a key mediator of systemic inﬂammatory
responses that is secreted by the anterior pituitary gland and
immune cells, mainly T cells. It stimulates the expression and
secretion of pro-inﬂammatory cytokines including TNF-a, IFN-g,
IL-1b, IL-6, and IL-8.22 Our study conﬁrmed that a group of patients
who died rapidly due to severe sepsis had signiﬁcant incremental
elevations in MIF and IL-10 levels. In future studies, it will be our
highest priority, and interesting to investigate, whether pro-
inﬂammatory cytokines secreted by Th1 cells are produced under
the dual effects of high MIF and IL-10 levels in severely septic
patients with RFO. The differential expression proﬁle of Th1/Th2
cells in patients with severe sepsis and the different outcomes will
also be included in future studies.
Several limitations of this study should be mentioned. First, the
number of patients in the RFO group was limited due to difﬁculties
in obtaining informed consent signed by legal representatives,
especially for patients whose condition was rapidly deteriorating.
Second, the role of other cytokines that have been studied at the
time of sepsis using cytokine multiplex analysis16,17 could not be
determined in this study because of the single-point blood
sampling design. Third, the lymphocytes from our patients could
not be further evaluated because, due to the design of this study,
we did not collect the peripheral blood mononuclear cells. Further
prospective studies are needed to explore the relationships
between serial multiple cytokine levels and lymphocyte expres-
sion in severe septic patients with different outcomes. In summary,
our study revealed both MIF and IL-10 to be spontaneously
produced in the early phase of severe sepsis, and incremental
elevations in these cytokines were found to be independently
associated with RFO in patients with severe sepsis. Whether the
spontaneous appearance of both MIF and IL-10 affects the
expression of Th1/Th2-related cytokines in patients with severe
sepsis, and thereby shapes the different outcomes, deserves further
investigation.Acknowledgements
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